Clinical importance of circulating immune complexes in human acute lymphoblastic leukemia

Autores
Croce, María Virginia; Fejes, Marcela; Riera, Norma; Minoldo, D. A.; Segal-Eiras, Amada
Año de publicación
1985
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
A total of 122 sera from acute lymphoblastic leukemia (ALL) patients were analyzed for circulating immune complexes (CIC) by two methods: the 125I-C1q binding assay and the polyethylene glycol precipitation test (PEG). The results were correlated with induction, remission and relapse stages of the disease. Using the first method the levels of CIC in induction were 15.18±9.15, with 19/29 positive cases (65.50%), P<0.001 compared with controls. In the remission phase the levels were 9.02±5.62, 11/45 (24.49%) nonsignificant P value, and in relapse they were 16.14±11.17 28/48 (58.33%) P<0.001. The PEG precipitation test results were: 0.33±0.10, 8/22 (36.36%); 0.24±0.11, 10/48 (20.83%) and 0.28±0.10, 6/28 (21.42%), respectively. Thus the values of CIC as measured by PEG in the three clinical of phases ALL did not differ significantly from controls. This contrasts with results obtained by the radioiodinated C1q binding assay, where the incidence of positive values was significantly higher in induction and in relapse and lower in the remission phase. These observations were extended in sequential vertical studies performed in a group of patients. These results suggest that raised CIC detected by the 125I-C1q method may reflect a progressive state in ALL and that quantitation of these immune complexes may provide an adequate biochemical marker for prognosis.
Facultad de Ciencias Médicas
Materia
Ciencias Médicas
Medicina
acute lymphoblastic leukemia
circulating immune complexes
polyethylene glycol
Nivel de accesibilidad
acceso abierto
Condiciones de uso
http://creativecommons.org/licenses/by-nc-sa/4.0/
Repositorio
SEDICI (UNLP)
Institución
Universidad Nacional de La Plata
OAI Identificador
oai:sedici.unlp.edu.ar:10915/131342

id SEDICI_e844c65c1d380d75ebecc1a18b8f7872
oai_identifier_str oai:sedici.unlp.edu.ar:10915/131342
network_acronym_str SEDICI
repository_id_str 1329
network_name_str SEDICI (UNLP)
spelling Clinical importance of circulating immune complexes in human acute lymphoblastic leukemiaCroce, María VirginiaFejes, MarcelaRiera, NormaMinoldo, D. A.Segal-Eiras, AmadaCiencias MédicasMedicinaacute lymphoblastic leukemiacirculating immune complexespolyethylene glycolA total of 122 sera from acute lymphoblastic leukemia (ALL) patients were analyzed for circulating immune complexes (CIC) by two methods: the 125I-C1q binding assay and the polyethylene glycol precipitation test (PEG). The results were correlated with induction, remission and relapse stages of the disease. Using the first method the levels of CIC in induction were 15.18±9.15, with 19/29 positive cases (65.50%), P<0.001 compared with controls. In the remission phase the levels were 9.02±5.62, 11/45 (24.49%) nonsignificant P value, and in relapse they were 16.14±11.17 28/48 (58.33%) P<0.001. The PEG precipitation test results were: 0.33±0.10, 8/22 (36.36%); 0.24±0.11, 10/48 (20.83%) and 0.28±0.10, 6/28 (21.42%), respectively. Thus the values of CIC as measured by PEG in the three clinical of phases ALL did not differ significantly from controls. This contrasts with results obtained by the radioiodinated C1q binding assay, where the incidence of positive values was significantly higher in induction and in relapse and lower in the remission phase. These observations were extended in sequential vertical studies performed in a group of patients. These results suggest that raised CIC detected by the 125I-C1q method may reflect a progressive state in ALL and that quantitation of these immune complexes may provide an adequate biochemical marker for prognosis.Facultad de Ciencias Médicas1985info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArticulohttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdf91-95http://sedici.unlp.edu.ar/handle/10915/131342enginfo:eu-repo/semantics/altIdentifier/issn/0340-7004info:eu-repo/semantics/altIdentifier/issn/1432-0851info:eu-repo/semantics/altIdentifier/doi/10.1007/bf00199780info:eu-repo/semantics/altIdentifier/pmid/3877563info:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by-nc-sa/4.0/Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)reponame:SEDICI (UNLP)instname:Universidad Nacional de La Platainstacron:UNLP2025-10-22T17:12:37Zoai:sedici.unlp.edu.ar:10915/131342Institucionalhttp://sedici.unlp.edu.ar/Universidad públicaNo correspondehttp://sedici.unlp.edu.ar/oai/snrdalira@sedici.unlp.edu.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:13292025-10-22 17:12:37.619SEDICI (UNLP) - Universidad Nacional de La Platafalse
dc.title.none.fl_str_mv Clinical importance of circulating immune complexes in human acute lymphoblastic leukemia
title Clinical importance of circulating immune complexes in human acute lymphoblastic leukemia
spellingShingle Clinical importance of circulating immune complexes in human acute lymphoblastic leukemia
Croce, María Virginia
Ciencias Médicas
Medicina
acute lymphoblastic leukemia
circulating immune complexes
polyethylene glycol
title_short Clinical importance of circulating immune complexes in human acute lymphoblastic leukemia
title_full Clinical importance of circulating immune complexes in human acute lymphoblastic leukemia
title_fullStr Clinical importance of circulating immune complexes in human acute lymphoblastic leukemia
title_full_unstemmed Clinical importance of circulating immune complexes in human acute lymphoblastic leukemia
title_sort Clinical importance of circulating immune complexes in human acute lymphoblastic leukemia
dc.creator.none.fl_str_mv Croce, María Virginia
Fejes, Marcela
Riera, Norma
Minoldo, D. A.
Segal-Eiras, Amada
author Croce, María Virginia
author_facet Croce, María Virginia
Fejes, Marcela
Riera, Norma
Minoldo, D. A.
Segal-Eiras, Amada
author_role author
author2 Fejes, Marcela
Riera, Norma
Minoldo, D. A.
Segal-Eiras, Amada
author2_role author
author
author
author
dc.subject.none.fl_str_mv Ciencias Médicas
Medicina
acute lymphoblastic leukemia
circulating immune complexes
polyethylene glycol
topic Ciencias Médicas
Medicina
acute lymphoblastic leukemia
circulating immune complexes
polyethylene glycol
dc.description.none.fl_txt_mv A total of 122 sera from acute lymphoblastic leukemia (ALL) patients were analyzed for circulating immune complexes (CIC) by two methods: the 125I-C1q binding assay and the polyethylene glycol precipitation test (PEG). The results were correlated with induction, remission and relapse stages of the disease. Using the first method the levels of CIC in induction were 15.18±9.15, with 19/29 positive cases (65.50%), P<0.001 compared with controls. In the remission phase the levels were 9.02±5.62, 11/45 (24.49%) nonsignificant P value, and in relapse they were 16.14±11.17 28/48 (58.33%) P<0.001. The PEG precipitation test results were: 0.33±0.10, 8/22 (36.36%); 0.24±0.11, 10/48 (20.83%) and 0.28±0.10, 6/28 (21.42%), respectively. Thus the values of CIC as measured by PEG in the three clinical of phases ALL did not differ significantly from controls. This contrasts with results obtained by the radioiodinated C1q binding assay, where the incidence of positive values was significantly higher in induction and in relapse and lower in the remission phase. These observations were extended in sequential vertical studies performed in a group of patients. These results suggest that raised CIC detected by the 125I-C1q method may reflect a progressive state in ALL and that quantitation of these immune complexes may provide an adequate biochemical marker for prognosis.
Facultad de Ciencias Médicas
description A total of 122 sera from acute lymphoblastic leukemia (ALL) patients were analyzed for circulating immune complexes (CIC) by two methods: the 125I-C1q binding assay and the polyethylene glycol precipitation test (PEG). The results were correlated with induction, remission and relapse stages of the disease. Using the first method the levels of CIC in induction were 15.18±9.15, with 19/29 positive cases (65.50%), P<0.001 compared with controls. In the remission phase the levels were 9.02±5.62, 11/45 (24.49%) nonsignificant P value, and in relapse they were 16.14±11.17 28/48 (58.33%) P<0.001. The PEG precipitation test results were: 0.33±0.10, 8/22 (36.36%); 0.24±0.11, 10/48 (20.83%) and 0.28±0.10, 6/28 (21.42%), respectively. Thus the values of CIC as measured by PEG in the three clinical of phases ALL did not differ significantly from controls. This contrasts with results obtained by the radioiodinated C1q binding assay, where the incidence of positive values was significantly higher in induction and in relapse and lower in the remission phase. These observations were extended in sequential vertical studies performed in a group of patients. These results suggest that raised CIC detected by the 125I-C1q method may reflect a progressive state in ALL and that quantitation of these immune complexes may provide an adequate biochemical marker for prognosis.
publishDate 1985
dc.date.none.fl_str_mv 1985
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Articulo
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://sedici.unlp.edu.ar/handle/10915/131342
url http://sedici.unlp.edu.ar/handle/10915/131342
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/issn/0340-7004
info:eu-repo/semantics/altIdentifier/issn/1432-0851
info:eu-repo/semantics/altIdentifier/doi/10.1007/bf00199780
info:eu-repo/semantics/altIdentifier/pmid/3877563
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-sa/4.0/
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
eu_rights_str_mv openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc-sa/4.0/
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
dc.format.none.fl_str_mv application/pdf
91-95
dc.source.none.fl_str_mv reponame:SEDICI (UNLP)
instname:Universidad Nacional de La Plata
instacron:UNLP
reponame_str SEDICI (UNLP)
collection SEDICI (UNLP)
instname_str Universidad Nacional de La Plata
instacron_str UNLP
institution UNLP
repository.name.fl_str_mv SEDICI (UNLP) - Universidad Nacional de La Plata
repository.mail.fl_str_mv alira@sedici.unlp.edu.ar
_version_ 1846783488708050944
score 12.982451